Back to Search Start Over

Findings on Multiple Myeloma Detailed by Investigators at Bristol-Myers Squibb Company (Pharmacodynamic Changes In Tumor and Immune Cells Drive Iberdomide's Clinical Mechanisms of Activity In Relapsed and Refractory Multiple Myeloma)

Findings on Multiple Myeloma Detailed by Investigators at Bristol-Myers Squibb Company (Pharmacodynamic Changes In Tumor and Immune Cells Drive Iberdomide's Clinical Mechanisms of Activity In Relapsed and Refractory Multiple Myeloma)

Source :
Hematology Week. July 29, 2024, 113
Publication Year :
2024

Abstract

2024 JUL 29 (NewsRx) -- By a News Reporter-Staff News Editor at Hematology Week -- A new study on Oncology - Multiple Myeloma is now available. According to news reporting [...]

Details

Language :
English
ISSN :
1543673X
Database :
Gale General OneFile
Journal :
Hematology Week
Publication Type :
News
Accession number :
edsgcl.802832550